Grifols, S.A. (NASDAQ:GRFS – Get Free Report)’s share price shot up 2.2% during mid-day trading on Tuesday . The stock traded as high as $7.34 and last traded at $7.34. 572,556 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 2,175,915 shares. The stock had previously closed at $7.18.
Grifols Price Performance
The company has a quick ratio of 1.29, a current ratio of 1.68 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $4.94 billion, a PE ratio of 7.18 and a beta of 0.49. The firm’s fifty day simple moving average is $7.38 and its 200-day simple moving average is $7.25.
Grifols (NASDAQ:GRFS – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The company had revenue of $1.96 billion for the quarter. On average, research analysts forecast that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Articles
- Five stocks we like better than Grifols
- Consumer Staples Stocks, Explained
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- How to Calculate Stock Profit
- Lowe’s Stock: Hold Now, Buy it When it Dips
- With Risk Tolerance, One Size Does Not Fit All
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.